AOD-9604 (hGH Fragment 176-191): What the Published Research Reports

AOD-9604 is a synthetic peptide corresponding to a lipolytic fragment synthesised from the C-terminus of human growth hormone (hGH) [2]. The published literature on this fragment is small and falls into two distinct areas: preclinical metabolic pharmacology in rodents, and analytical work relevant to anti-doping test methodology. The principal preclinical characterisation was conducted in mice. Heffernan and colleagues reported that chronic intraperitoneal administration of both hGH and AOD9604 reduced body weight and body fat in obese mice [2]. In that animal model, the observed changes correlated with increased expression of beta(3)-adrenergic receptor (beta(3)-AR) RNA, described by the authors as the major lipolytic receptor found in fat cells, and both hGH and AOD9604 raised the repressed beta(3)-AR RNA levels seen in obese mice toward levels comparable with lean mice [2]. The same animal study used beta(3)-AR knock-out mice to probe mechanism. Long-term treatment with hGH or AOD9604 in the knock-out animals did not produce the change in body weight or the increase in lipolysis that was observed in wild-type control mice [2]. In an acute experiment in the same knock-out strain, however, AOD9604 was reported to increase energy expenditure and fat oxidation [2]. The authors concluded that the lipolytic actions of hGH and AOD9604 are not mediated directly through the beta(3)-AR, while noting that both compounds increase beta(3)-AR expression, which the authors suggested may subsequently contribute to enhanced lipolytic sensitivity [2]. These findings were generated in mice; no equivalent human metabolic outcome data appear in the retrieved set. Separately, an analytical investigation examined whether AOD-9604 interferes with the WADA hGH isoform differential immunoassay. Orlovius and colleagues reported that AOD-9604 does not influence that immunoassay [1]. This is a methodological finding about assay behaviour and detection, not a metabolic or physiological outcome, and it does not speak to the effects described in the rodent work [1][2]. Taken together, the available literature in this set characterises AOD-9604 as an hGH-derived fragment whose lipid-metabolism effects have been described in obese and genetically modified mice [2], alongside a single analytical report addressing its behaviour in an hGH isoform immunoassay [1]. Researchers designing further work should note that mechanistic conclusions regarding beta(3)-AR involvement derive entirely from the murine model [2].